Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
From Horizon Therapeutics plc
Via Business Wire
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
Executives Sell More Than $262M Of 5 Stocks
Although gold futures traded higher on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
Via Benzinga
New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
From Horizon Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
Via Investor's Business Daily
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22%... 
Via Benzinga
Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales
Horizon Therapeutics plc's (NASDAQ: HZNP) Q4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million. The adjusted gross profit declined... 
Via Benzinga
Horizon Therapeutics: Q4 Earnings Insights
Horizon Therapeutics (NASDAQ:HZNP) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
From Horizon Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Insider Buying Detected – Buy This Biotech Now
Biotech and pharmaceutical research are the hottest growing sectors in the global business market, brought into the public eye by the onset of the COVID-19 pandemic. 
Via Talk Markets
Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation
Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis... 
Via Benzinga
Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
From Horizon Therapeutics plc
Via Business Wire
New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named Title Partner of the Irish Open
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
From Horizon Therapeutics plc
Via Business Wire
Death Cross Looms Over Horizon Therapeutics Investors
If history is any guide, there may be trouble ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "death cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Horizon Therapeutics plc
Via Business Wire
7 of the Top-Rated Pharmaceutical Stocks for Q1
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.